Literature DB >> 12057158

Papillary thyroid cancer.

J H Yim1, G M Doherty.   

Abstract

Papillary thyroid cancer is the most common neoplasm of the thyroid gland. Surgical resection is the cornerstone of therapy. There is controversy regarding the extent of resection, ranging from thyroid lobectomy plus isthmusectomy to total thyroidectomy, but in experienced hands total thyroidectomy has many significant advantages over a lesser operation. Nonoperative therapy has no role as primary therapy for papillary thyroid cancer, but can be used in conjunction with surgery to improve outcome. Radioiodine in patients who have received total thyroidectomy can be used to identify residual occult tumor, recurrence, and metastasis, and can also be used to ablate the neoplasm, resulting in a substantial cure rate. Thyroid hormone is needed as replacement after total thyroidectomy, but can also be given as thyroid-stimulating hormone suppression, which may have an adjunctive benefit after resection.

Entities:  

Mesh:

Year:  2000        PMID: 12057158     DOI: 10.1007/s11864-000-0048-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  50 in total

1.  Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study.

Authors:  G T Krishnamurthy; W H Blahd
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

2.  Papillary carcinoma of the thyroid. I. Developing pattern of metastasis.

Authors:  S Noguchi; A Noguchi; N Murakami
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

3.  External radiotherapy and radionuclide in the treatment of thyroid cancer.

Authors:  M Tubiana
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

4.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

5.  [Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. I. Peripheral blood changes].

Authors:  O Schober; H H Günter; R Schwarzrock; H Hundeshagen
Journal:  Strahlenther Onkol       Date:  1987-07       Impact factor: 3.621

6.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

Review 7.  Thyroid cancer.

Authors:  O H Clark; Q Y Duh
Journal:  Med Clin North Am       Date:  1991-01       Impact factor: 5.456

8.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

9.  High-risk thyroid cancer. Prolonged survival with early multimodality therapy.

Authors:  B G Durie; D Hellman; J M Woolfenden; R O'Mara; M Kartchner; S E Salmon
Journal:  Cancer Clin Trials       Date:  1981

10.  The morbidity of total thyroidectomy.

Authors:  E F Scanlon; J E Kellogg; D P Winchester; R H Larson
Journal:  Arch Surg       Date:  1981-05
View more
  2 in total

1.  Familial Adenomatous Polyposis-Associated Papillary Thyroid Cancer.

Authors:  Shahrun Niza Abdullah Suhaimi; Nadzrin Nazri; Mat Latar Nani Harlina; Nurismah Md Isa; Rohaizak Muhammad
Journal:  Malays J Med Sci       Date:  2015 Jul-Aug

2.  Cribiform-morular variant of papillary thyroid carcinoma and familial adenomatous polyposis: Report of a case.

Authors:  Mario Giuffrida; Federica De Giorgi; Federico Cozzani; Matteo Rossini; Elena Bonati; Paolo Del Rio
Journal:  Acta Biomed       Date:  2021-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.